Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 245-250

  Brožič, Petra ^a   Turk, Samo ^a   Lanišnik Rižner, Tea ^a   Gobec, Stanislav ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

AKR1C1 inhibitors; eHiTS; NCI "Diversity Set"; Virtual high throughput screening

Indexed keywords

ALDO KETO REDUCTASE 1C1 INHIBITOR; ENZYME INHIBITOR; NSC 1012; NSC 10460; NSC 116702; NSC 128609; NSC 13987; NSC 18877; NSC 23583; NSC 28136; NSC 282027; NSC 28311; NSC 292213; NSC 31698; NSC 327705; NSC 328087; NSC 33052; NSC 34352; NSC 35489; NSC 36369; NSC 371684; NSC 371876; NSC 371884; NSC 372046; NSC 41550; NSC 41663; NSC 42384; NSC 47932; NSC 48168; NSC 48708; NSC 5844; NSC 67690; NSC 74702; NSC 7510; NSC 7810; NSC371884; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANESTHESIA; ANTICONVULSANT ACTIVITY; ARTICLE; CATAMENIAL EPILEPSY; DEPRESSION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOMETRIUM CANCER; IC 50; MOLECULAR DOCKING; PREGNANCY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ALCOHOL OXIDOREDUCTASES; BIOCATALYSIS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 60249087561     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.002     Document Type: Article

References (19)

1. Bauman D.R., Rudnick S., Szewczuk L.M., Jin Y., Gopishetty S., and Penning T.M. Development of non-steroidal anti-inflammatory drug (NSAID) analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol. Pharmacol. 67 (2005) 60-68
2. Brožič P., Šmuc T., Gobec S., and Lanišnik Rižner T. Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1. Mol. Cell. Endocrinol. 259 (2006) 30-42
3. Couture J.F., Cantin L., Legrand P., Luu-The V., Labrie F., and Breton R. Expression, crystallization and preliminary X-ray analysis of human and rabbit 20α-hydroxysteroid dehydrogenases in complex with NADP(H) and various steroid substrates. Acta Crystallogr. D 58 (2002) 135-139
4. Couture J.-F., Legrand P., Cantin L., Luu-The V., Labrie F., and Breton R. Human 20α-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J. Mol. Biol. 331 (2003) 593-604
5. Dhagat U., Carbone V., Chung R.P.-T., Matsunaga T., Endo S., Hara A., and El-Kabbani O. A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20α-hydroxysteroid dehydrogenase. Med. Chem. 3 (2007) 546-550
6. Dufort I., Labrie F., and Luu V. Human types 1 and 3 3α-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J. Clin. Endocrinol. Metab. 86 (2001) 841-846
7. Dufort I., Rheault P., Huang X.F., Soucy P., and Luu V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140 (1999) 568-574
8. Griffin L.D., and Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13512-13517
9. Guido R.V.C., Oliva G., and Andricopul A.D. Virtual screening and its integration with modern drug design technologies. Curr. Med. Chem. 15 (2008) 37-46
10. Higaki Y., Usami N., Shintani S., Ishikura S., El-Kabbani O., and Hara O. Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem. Biol. Interact. 143-144 (2003) 503-514
11. Jornvall H., Persson B., Krook M., Atrian S., Gonzales-Duarte R., Jefferey J., and Ghosh D. Short-chain dehydrogenase/reductases (SDRs). Biochemistry 34 (1995) 6003-6013
12. Lanišnik Rižner T., Šmuc T., Rupreht R., Šinkovec J., and Penning T.M. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol. Cell. Endocrinol. 248 (2006) 126-135
13. Nobel S., Abrahamsen L., and Oppermann U. Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur. J. Biochem. 268 (2001) 4113-4125
14. Penning T.M., Burczynski M.E., Jez J.M., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of sex hormones. Biochem. J. 351 (2000) 67-77
15. Penning T.M. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Hum. Reprod. Update 9 (2003) 193-205
16. Persson B., Krook M., and Jornvall H. Characteristics of short-chain alcohol dehydrogenases and related enzymes. Eur. J. Biochem. 200 (1991) 537-543
17. Usami N., Yamamoto T., Shintani S., Higaki Y., Ishikura S., Katagiri Y., and Hara A. Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 25 (2002) 441-445
18. Zsoldos Z., Reid D., Simon A., Sadjad B., and Johnson A.P. A new fast, exhaustive flexible ligand docking system. J. Mol. Graph. Model. 7 (2006) 198-212
19. Zsoldos Z., Simon A., Reid D., Sadjad B., and Johnson A.P. eHiTS: an innovative approach to the docking and scoring function problems. Curr. Prot. Pept. Sci. 7 (2006) 421-435